XUETING HUANG¹, CHAOJIE XU², CHEN LI^3,*, ZHIXIAN PAN^1,*

BIOCELL, Vol.48, No.12, pp. 1805-1813, 2024, DOI:10.32604/biocell.2024.056431 - 30 December 2024

Abstract Background: Hyperuricemia is a metabolic disorder which is characterized by increased serum uric acid levels, which can contribute to serious health issues such as gout, cardiovascular disease, and kidney damage. Epigenetic modifications, for example, DNA methylation, exert a crucial function in gene regulation and have been implicated in various metabolic disorders. The ATP-Binding Cassette Subfamily G Member 2 (ABCG2) gene is involved in uric acid excretion, and its expression can be influenced by methylation of its promoter region. Methods: This study involved the design of three guide RNA (gRNA) sequences targeting specific CpG sites within… More >

MAHER KURDI^1,*, ALAA ALKHOTANI², ABDULRAHMAN SABBAGH³, EYAD FAIZO⁴, AHMED I. LARY⁵, AHMED K. BAMAGA⁶, MAJID ALMANSOURI⁷, BADR HAFIZ⁸, THAMER ALSHARIF⁹, SALEH BAEESA⁸

Oncology Research, Vol.32, No.6, pp. 1037-1045, 2024, DOI:10.32604/or.2024.051112 - 23 May 2024

Abstract Background: The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described. Methods: A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated. Results: Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype… More > Graphic Abstract

YOULIN TUO, XUBAO LIU^*

BIOCELL, Vol.47, No.2, pp. 319-328, 2023, DOI:10.32604/biocell.2023.025250 - 18 November 2022

Abstract Retinoic acid receptor responder 3 (RARRES3) has been characterized as a tumor suppressor in multiple types of cancer. This study aimed to examine the expression profile of RARRES3 across the PAM50 subtypes of breast cancer. The DNA methylation status of RARRES3 was checked in the basal-like subtype, and the underlying mechanisms of its dysregulation were explored. RNA-sequencing (seq) and methylation data from The Cancer Genome Atlas were used for in-silico analysis. Basal-like representative SUM149 and MDA-MB-468 cell lines were used for in vitro and in vivo studies. Compared to tumor-adjacent normal tissues, only the basal-like tumor tissues had… More >